Subtopic Deep Dive
Quinazolinone Kinase Inhibitors
Research Guide
What is Quinazolinone Kinase Inhibitors?
Quinazolinone kinase inhibitors are quinazolinone-based small molecules designed to selectively inhibit tyrosine kinases such as EGFR for cancer therapy.
Researchers synthesize quinazolinone derivatives targeting EGFR and other kinases to combat oncogenic signaling in tumors. Structure-activity relationships guide optimization for potency and selectivity. Over 10 key papers since 2013 document synthesis and bioactivity, with Asif (2014) cited 202 times.
Why It Matters
Quinazolinone kinase inhibitors enable precision oncology by blocking EGFR in resistant cancers, as shown in Le et al. (2020) with 3-methyl-quinazolinone derivatives inhibiting EGFR-wt-TK in cell lines. Haider et al. (2022) highlight dual EGFR/VEGFR inhibition for improved antitumor efficacy. Negi and Ahmad (2017) review quinazoline scaffolds overcoming resistance in clinical settings.
Key Research Challenges
Selectivity Over Kinases
Achieving selectivity for EGFR amid similar ATP-binding pockets in kinases remains difficult. Haider et al. (2022) note off-target effects limit clinical translation. Structure modifications are needed to enhance specificity.
Overcoming Resistance
Tumors develop resistance via mutations like T790M in EGFR. Le et al. (2020) evaluate inhibitors against resistant cell lines but face potency challenges. New scaffolds must address secondary mutations.
Synthetic Scalability
Efficient synthesis of diverse quinazolinone libraries for SAR studies is constrained by multi-step reactions. Auti et al. (2020) discuss hybridization strategies but scalability issues persist. Green chemistry methods are required.
Essential Papers
Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids
Prashant S. Auti, Ginson George, Atish T. Paul · 2020 · RSC Advances · 295 citations
Recent advances in quinazoline/quinazolinone hybrid heterocycles in medicinal chemistry and their pharmacological diversification.
Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives
Mohammad Asif · 2014 · International Journal of Medicinal Chemistry · 202 citations
The heterocyclic fused rings quinazoline and quinazolinone have drawn a huge consideration owing to their expanded applications in the field of pharmaceutical chemistry. Quinazoline and quinazolino...
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents
Devendra Singh Negi, Irshad Ahmad · 2017 · MedChemComm · 195 citations
This article reviews the recent advances in the development of quinazoline derivatives as anticancer agents.
Quinazoline derivatives: synthesis and bioactivities
Dan Wang, Feng Gao · 2013 · Chemistry Central Journal · 189 citations
Synthesis, characterization and apoptotic activity of quinazolinone Schiff base derivatives toward MCF-7 cells via intrinsic and extrinsic apoptosis pathways
Maryam Zahedifard, Fadhil Lafta Faraj, Mohammadjavad Paydar et al. · 2015 · Scientific Reports · 96 citations
Design, synthesis and <i>in vitro</i> biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
Yi Le, Yiyuan Gan, Yihong Fu et al. · 2020 · Journal of Enzyme Inhibition and Medicinal Chemistry · 78 citations
In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity <i>in vitro</i> on wild type epidermal growth factor receptor tyro...
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-<i>d</i>]pyrimidine scaffold
Daniel J. Baillache, Asier Unciti‐Broceta · 2020 · RSC Medicinal Chemistry · 76 citations
Pyrazolo[3,4-<italic>d</italic>]pyrimidines have become of significant interest for the medicinal chemistry community as a privileged scaffold for the development of kinase inhibitors to treat a ra...
Reading Guide
Foundational Papers
Start with Asif (2014, 202 citations) for synthesis/biology overview, then Wang and Gao (2013, 189 citations) for bioactivities to build core knowledge.
Recent Advances
Study Le et al. (2020) for EGFR inhibitor design, Haider et al. (2022) for SAR reviews, and Auti et al. (2020) for hybrids.
Core Methods
Core techniques: Niementowski condensation, phase-transfer alkylation (Ouyang et al., 2006), EGFR kinase assays, docking simulations (Abdullahi et al., 2022).
How PapersFlow Helps You Research Quinazolinone Kinase Inhibitors
Discover & Search
Research Agent uses searchPapers('quinazolinone EGFR inhibitors') to find Le et al. (2020, 78 citations), then citationGraph reveals citing works on resistance, and findSimilarPapers expands to hybrids from Auti et al. (2020). exaSearch queries 'quinazolinone Src kinase selectivity' for niche results.
Analyze & Verify
Analysis Agent applies readPaperContent on Le et al. (2020) to extract IC50 data for EGFR, verifies claims with verifyResponse (CoVe) against Asif (2014), and runs PythonAnalysis to plot SAR trends from tables using pandas/matplotlib. GRADE grading scores evidence strength for clinical relevance.
Synthesize & Write
Synthesis Agent detects gaps in EGFR resistance coverage between Negi (2017) and Haider (2022), flags contradictions in bioactivity claims. Writing Agent uses latexEditText for SAR tables, latexSyncCitations with BibTeX from 10 papers, latexCompile for full review, and exportMermaid for kinase inhibition pathways.
Use Cases
"Analyze IC50 trends in quinazolinone EGFR inhibitors from recent papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas plot of Le et al. 2020 IC50 vs. substituents) → matplotlib graph of SAR trends.
"Draft LaTeX section on quinazolinone kinase SAR with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (SAR paragraph) → latexSyncCitations (Auti 2020, Haider 2022) → latexCompile → PDF with compiled equations.
"Find GitHub code for quinazolinone docking simulations"
Research Agent → paperExtractUrls (Haider 2022) → paperFindGithubRepo → githubRepoInspect → code for AutoDock quinazolinone-EGFR simulations.
Automated Workflows
Deep Research workflow scans 50+ quinazolinone papers via searchPapers → citationGraph → structured report on kinase targets with GRADE scores. DeepScan applies 7-step analysis: readPaperContent (Le et al. 2020) → CoVe verification → runPythonAnalysis on bioassay data → checkpoint critique. Theorizer generates hypotheses on hybrid scaffolds from Auti (2020) and Negi (2017) patterns.
Frequently Asked Questions
What defines quinazolinone kinase inhibitors?
Quinazolinone kinase inhibitors are heterocycles targeting tyrosine kinases like EGFR via ATP-site binding, optimized through SAR for cancer selectivity (Le et al., 2020).
What are key synthesis methods?
Common methods include Niementowski reaction variants and alkylations from quinazolin-4-ones, as detailed in Asif (2014) and Wang and Gao (2013).
What are landmark papers?
Asif (2014, 202 citations) covers biological potential; Le et al. (2020, 78 citations) reports EGFR inhibitors; Haider et al. (2022, 58 citations) reviews EGFR/VEGFR SAR.
What open problems exist?
Challenges include kinase selectivity, resistance mutations, and scalable synthesis, per Auti et al. (2020) and Haider et al. (2022).
Research Quinazolinone synthesis and applications with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Quinazolinone Kinase Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers